Pfizer Aktie News

Pfizer is testing a long-acting GLP-1 weight loss drug and seeing solid results. The company will report on trial results in June, and investors will be watching.

Pharma earnings weren't the main focus for drugmakers this quarter. "2025 was about understanding kind of the rules of the future of the game," McKinsey Senior Partner Greg Graves told CNBC.

Pfizer remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. PFE's non-COVID portfolio posted 6% operational growth in 2025, with international markets and Pfizer CentreOne driving resilience. Productivity initiatives are on track to deliver $7.2B in net cost savings, supporting margin improvement despite patent cliff and pricing headwinds.

One thing I've learned is the pendulum always swings. It is in our best approach to sell high and buy low. This has worked well for us, as our returns suggest.

Pfizer continues to lag the market due to poor financial results and upcoming challenges. However, the company is entering an important period in its clinical development.

Eli Lilly has a lofty 46 price-to-earnings ratio. Two other drugmakers have P/Es that are less than half of Eli Lilly's P/E.

Choosing the right investment vehicles can ensure steady income and wealth generation.

Pfizer (PFE) is confronting challenges. Even the most prominent companies are not beyond reach.